Mr. Francois Roberge reports

LSL PHARMA GROUP ANNOUNCES REDEMPTION OF 11% UNSECURED CONVERTIBLE DEBENTURES

TSX Trust Company, in accordance with the trust indenture dated Nov. 1, 2023, between LSL Pharma Group Inc. and the trustee, will provide notice of early redemption of all of the corporation's outstanding $3,288,000 aggregate principal amount of 11 per cent unsecured convertible debentures, originally due Oct. 31, 2028. The convertible debentures will be redeemed by the trustee on Aug. 4, 2025, in accordance with the terms of the indenture. The convertible debentures, which are listed and posted for trading on the TSX Venture Exchange under the symbol LSL.DB, will cease trading on the redemption date in accordance with TSX-V policies.

On the redemption date, the trustee will pay holders of convertible debentures a redemption price equal to $10.40 for each $10 principal amount of convertible debentures (which includes the early repayment premium required pursuant to the indenture) plus all accrued and unpaid interest up to but excluding the redemption date.

Beneficial holders of the convertible debentures are encouraged to contact their investment dealer to co-ordinate the surrender of their convertible debentures or if they have any questions about the redemption. No action is required to be taken by holders of the convertible debentures in connection with the redemption.

About LSL Pharma Group Inc.

LSL Pharma is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Companies forming part of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Sante Inc. and Dermolab Pharma Ltd.

We seek Safe Harbor.